Using Mounjaro During Perimenopause: What We Know and What to Discuss With Your Doctor

What the trial data tells us about tirzepatide and weight in this hormonal context

SURMOUNT-1, a 72-week randomised trial published in the New England Journal of Medicine, found that tirzepatide at 15 mg produced an average body-weight reduction of around 20–21% compared with placebo in adults with obesity. The trial enrolled thousands of adults across a broad age range and included people with conditions common in the perimenopausal years, such as hypertension and dyslipidaemia. It did not stratify results by menopausal status, so there is no published subgroup analysis confirming or denying a differential effect in perimenopausal women specifically, that gap in the evidence is worth being clear about.

What we do know from broader endocrinology research is that insulin resistance rises as oestrogen falls, and that visceral fat accumulation accelerates during the menopause transition. Tirzepatide's dual action on GIP and GLP-1 receptors addresses both appetite regulation and insulin sensitivity, which is mechanistically relevant to this pattern of weight gain, though translating mechanism into a guarantee of outcome for any individual is something no responsible clinician would do. The NICE technology appraisal TA1026, which recommends tirzepatide for weight management in adults meeting the eligibility criteria, does not exclude perimenopausal women as a group.

If you are curious about the broader relationship between tirzepatide and the menopause transition, our page on Mounjaro and perimenopause covers the mechanism in more depth.

HRT, oral contraceptives and tirzepatide: the absorption question that matters here

This is the most practically important clinical detail for anyone in perimenopause considering Mounjaro. Tirzepatide slows gastric emptying, the rate at which the stomach passes food and medicines into the small intestine. For most medicines this is not clinically significant, but for oral formulations absorbed in the gut, timing and consistency can matter.

NHS England's guidance on weight-management injections specifically flags two points for women on tirzepatide. First, those using oral contraceptive pills should use an additional non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. Second, for women using HRT, transdermal forms (patches, gels, sprays) are worth discussing with a GP or menopause specialist because they bypass the gut altogether and avoid any theoretical absorption interaction. Oral HRT tablets are not contraindicated, but the conversation is worth having before you start treatment rather than after. These points are drawn directly from NHS England's wraparound care guidance for weight-management injections.

Neither of these points means Mounjaro and HRT cannot be used together, they can, and many women do use both. It means the combination needs to be actively discussed with the clinicians managing both treatments. If you want to understand whether Mounjaro helps with menopause symptoms as well as weight, our dedicated page looks at that question in detail alongside the menopause-specific picture.

What remains uncertain, and who to talk to

Honest medicine means saying clearly what the evidence does not cover. There are no large published trials examining tirzepatide specifically in perimenopausal women, no data on whether the hormonal flux of perimenopause alters weight-loss response, and no guidance from NICE or the MHRA that addresses this life stage as a distinct clinical category. What exists are the licensed eligibility criteria (BMI ≥30, or ≥27 with a weight-related condition), the mechanistic rationale, and individual clinical judgement.

If you are managing perimenopause with a specialist (a gynaecologist or a menopause clinic) looping them in alongside any weight-management prescriber is the right approach. If you are considering Mounjaro through a private route, a prescriber will review your full medical history, including any HRT you take, your contraception, your cardiovascular risk and your current weight. That review is the point at which suitability is determined, not before it. It is also worth noting that women who become pregnant during treatment should read our guidance on using Mounjaro during pregnancy, as the advice in that situation is distinct.

A note on side effects in this context: the most common effects of tirzepatide are gastrointestinal (nausea, loose stools, reflux, reduced appetite) and these tend to be most noticeable at the start of treatment or after a dose change, then settle. They overlap with some perimenopausal symptoms, which can make attribution tricky. The NHS tirzepatide page lists the full side-effect profile; any new or severe symptom, particularly persistent stomach pain radiating to the back, warrants prompt medical advice. If you have questions our team has not yet answered, the faqs page is a good starting point, and our page on drinking alcohol on Mounjaro is worth a read if that is relevant to your lifestyle, or you can reach out via our contact page. For a fuller look at how this medication intersects with hormonal change, our pages on Mounjaro and menopause and menopause and tirzepatide explore those questions in more detail.

If you'd like to explore whether treatment is right for your situation, check your eligibility with a free consultation. A real prescriber reads every submission the same day, usually well before the 12 o'clock cut-off if you get in early.